MYCOPHENOLATE MOFET1L (MMF), which is a
powerful antiproliferative agent that selectively inhibits
DNA synthesis in lymphocytes, has been shown in
recent control trials to reduce the incidence of acute
rejection in recipients of cadaver renal allografts when used
prophylactically in combination with Cyclosporine (CyA)
and Prednisone.la MMF has also been shown to be successful
in the treatment of refractory kidney transplant
rejection.' However, there is little data about the use of
MMF in the prophylactic treatment of renal allografts from
Living genetically related or emotionally related donors. To
assess the potential value of MMF in this group of recipients,
we carried out the following preliminary study, where
MMF was used in such recipients who had high risk medical
conditions that often cause |
